Company Overview of Laidlaw & Company (UK) Ltd.
Laidlaw & Company (UK) Ltd. provides investment banking and wealth management services to institutions and individuals in the United States and the United Kingdom. Its investment banking services include capital raising through placement of equity with institutional and high net worth retail investors; placement of debt and mezzanine capital with institutional investors; acquisition financing; arrangement of national exchange listings; the United States trading markets; AIM-listed transactions in the United Kingdom market; and initial public offerings. The company’s investment banking services also comprise advisory services on acquisitions, divestitures, fairness opinions, financial restruc...
546 5th Avenue
New York, NY 10036
Key Executives for Laidlaw & Company (UK) Ltd.
Managing Partner and Head of Capital Markets
Executive Director of Investment Banking and Head of Laidlaw Private Equity
Senior Managing Director, Private Placements
Compensation as of Fiscal Year 2016.
Laidlaw & Company (UK) Ltd. Key Developments
Relmada Therapeutics, Inc. Files Amended Complaint Against Laidlaw & Company (UK) Ltd
Jan 26 16
Relmada Therapeutics Inc. announced that it has filed a motion to amend its complaint against Laidlaw &Company (UK) Ltd. (Laidlaw) in the U.S. District Court for the District of Nevada. The motion to file an amended complaint is part of the lawsuit that the company had previously filed in the Nevada District Court. The amended complaint includes an additional legal claim based on Laidlaw's breach of the fiduciary duty that it owed to Relmada when Laidlaw disclosed confidential information that it acquired in its capacity as the company's investment banker. Relmada is also seeking monetary damages arising from fees and costs that it incurred responding to Laidlaw's false and misleading proxy materials in December 2015. Relmada noted that the Nevada court previously issued a temporary restraining order and associated injunction against Laidlaw and its principals, Matthew Eitner and James Ahern, as a result of their dissemination of false and misleading proxy materials. Relmada's Board believes Laidlaw must compensate the Company for the damages it has suffered as a result of Laidlaw's actions, and that Laidlaw must be prevented from harming the company in the future.
Laidlaw & Company, LTD. Announces Executive Changes
Jan 12 16
Laidlaw & Company, LTD. announced the expansion of the London office with the addition of two team member: Richard Michalski, Senior Managing Director in Wealth Management and Bryan Kobel, Managing Director in Equity Capital Markets. The team will look to build on the current infrastructure and client base in the Wealth Management division and provide European healthcare companies and investors access to the US capital markets. Mr. Richard Michalski joined Laidlaw & Co. (Ltd) as Senior Managing Director in November 2010 from Aegis Capital, where he was a Senior Vice President. Mr. Bryan Kobel joined Laidlaw & Co. (Ltd) in March of 2012 from a small cap consulting company. Most recently, he was instrumental in helping to develop the US capital markets presence of Laidlaw & Co. since joining.
Relmada Therapeutics, Inc. Files Lawsuit against Laidlaw & Company and its Principals to Protect Interests of Relmada Stockholders
Dec 9 15
Relmada Therapeutics Inc. announced that it has filed a lawsuit against Laidlaw & Company (UK) Ltd. and its two principals, Matthew Eitner and James Ahern, in the U.S. District Court for the District of Nevada. Laidlaw previously served as an investment banker to Relmada. Using shares and confidential information gained from these services to Relmada, Laidlaw recently launched a contest to take effective control of the Company. Laidlaw and its principals have a history of violating U.S. financial regulations, which has resulted in numerous customer complaints, regulatory sanctions and monetary penalties. In its lawsuit, Relmada claims that Laidlaw and its principals are once again violating U.S. laws and regulations, including disseminating materially false and misleading information in its attempt to take effective control of Relmada. The lawsuit filed by Relmada claims that Laidlaw failed to comply with Securities and Exchange Commission (SEC) regulations, Relmada's Articles of Incorporation and Bylaws, and Nevada law, and seeks to enjoin Laidlaw from continuing to disseminate false and misleading information and from soliciting proxies from Relmada stockholders under false and misleading pretenses, and to correct the misinformation it has already issued.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|